For these reasons, meta-analyses in this field (Samara et al., 2016; Chakos et al., 2001) could include heterogeneous samples, in part due to unclear or lax TRS definitions. Hence, they are less helpful when searching for evidence based treatment recommendations for TRS (Miyamoto et al., 2015) . Another important factors that contribute to this heterogeneity among studies are: dosage differences, investigator bias combined with the difficulty of blinding clozapine treatment assignment, and the effect of prior antipsychotic treatment (Kane and Correll, 2016) .
We performed a systematic and critical review of current literature about efficacy of drugs in well-defined TRS. We analyzed key aspects of methodology and quality, definitions of resistance and response, efficacy variables (response rate and mean improvement) and safety outcomes. Here, in this letter, our aim is to present our conclusions about the antipsychotics efficacy and the problems affecting the interpretation of studies on TRS.
Double-blinded randomized trials (DBRT) on TRS were searched by: 1. a systematic search in April 2015 by the following search strategy: schizophrenia[Title]) AND ("ultra-resistant" [Title] OR "treatment-refractory"[Title]) OR "treatment-resistant"[Title]) AND "English"[Language]) from Scopus, PubMed and CINAHL (EBSCO) databases, 2. manual search. We included only studies on treatment efficacy in a clear-defined TRS population according to criteria proposed by Suzuki et al. (2012) We found sixteen efficacy DBRT in TRS (Table 1) , that is notably smaller number compared to the last meta-analysis (Samara et al., 2016) . Nine compared clozapine versus non-clozapine antipsychotics and seven compared antipsychotics other than clozapine among themselves.
Among the seven non-clozapine trials, there were only two welldesigned studies with applicable results:
- Conley et al. (1998): showing no advantage in efficacy of olanzapine over chlorpromazine at 8 weeks (7% and 0% respectively). -Lal et al. (2006) : showing how high-doses of FGAs produce more neurological adverse events and they can be difficult to distinguish from symptoms associated with psychosis. The improvement in participants' psychopathology could be, at least in part, secondary to dose reduction.
The other five trials had many flaws which may lead to erroneous conclusions (i.e. lax TRS criteria, inclusion of intolerants or schizoaffective patients, unclear results presentation).
Results showed clozapine superiority over first-generation antipsychotics (FGA) in three of four well-designed trials with clear TRS definitions. However, clozapine did not demonstrate superiority over secondgeneration antipsychotics (SGA): in our meta-analytic calculation there was no statistically significant advantage for clozapine in terms of response (OR 0.94 [95% CI: 0.69-1.27]. The analysis included five studies, including in total 339 clozapine and 347 SGA treated patients. There were no sign of heterogeneity (chi 2 = 3.57, I2 = 0.0%, p = 0.47) and no indication of publication bias (Egger's test, z = −0.24, p = 0.999). Our results may be true finding, or be partly explained by 1) unclear eligibility criteria (i.e. mixing schizophrenia and schizoaffective patients), 2) unclear results presentation, 3) broad TRS definitions mixing intolerant patients. In fact, clozapine vs SGA trials achieved higher response rates compared to clozapine vs FGA trials (see Table 1 ). Another important issue was the lower clozapine doses in clozapine vs SGA trials. Regarding this, conclusions of meta-analysis by Samara and colleagues are very clear: "the underdosing in industry-funded trials could constitute a serious problem that could have affected the results". In addition, only few SGA have been compared with clozapine (i.e. ziprasidone, olanzapine, risperidone) and therefore, the efficacy in TRS-population of another SGAs remains unknown (e.g. amisulpride, aripiprazole, sertindole, quetiapine).
Non-clozapine polypharmacy and high-dose treatment in TRS are not supported by evidence. To our knowledge there are no studies in TRS population that compare clozapine monotherapy with non-clozapine polypharmacy, however there are two small open-trials (Kotler et al., 2004; Suzuki et al., 2008) offering discordant results.
Regarding high-dose treatment, there is only one DBRT (Meltzer et al., 2008) comparing high-dose of olanzapine (35 mg/d) versus clozapine (550 mg/d), showing similar response rates at 6 months (50% and 60% respectively). However, this industry supported study excluded patients who did not respond previously to olanzapine. This reveals another problem about inclusion of samples with different severity of treatment-resistance, since the TRS definition does not state exactly how effective antipsychotics should have been tried before clozapine. I.e. the samples with exclusion of patients who had failed trials of olanzapine may be considered less treatment-resistant than samples that have included non-responders to, for example, both olanzapine and risperidone. Underlining this issue, there is NIMH-sponsored study comparing high-dose of olanzapine (50 mg/d) versus clozapine (450 mg/d), that we did not include in the revision because it had a ITT intention to treat analysis, PP per-protocol analysis, CA completers analysis, BZT benzotropine, SAD schizoaffective disorder, SCZ schizophrenia patients, EPS extra-pyramidal symptoms, TRS treatment-resistant schizophrenia, FGA first-generation antipsychotics, SGA second-generation antipsychotics, RLAI risperidone long-acting injection, NR not reported. cross-over design and originally was a safety trial, showing better tolerability and response rate in clozapine (0% vs 30%) (Conley et al., 2003) .
In the review we did not include pragmatic studies because usually they applied a more liberal definition of treatment-resistance or they are not double-blinded (e.g. observational studies, population-based register studies, cost-effectiveness trials or open-label effectiveness trials). However, they may provide longitudinal results beyond acute response, they focus in other important outcomes (e.g. quality of life, social functions, discontinuation rate) and they also contribute to enhance our clinical practice. In fact, in many of these studies clozapine was superior to FGA and to SGA (McEvoy et al., 2006) .
To summarize, we know surprisingly little about optimal antipsychotic treatment of TRS. However, clozapine remains as the first-line treatment after a failure of two antipsychotic trials according to treatment guidelines (Gaebel et al., 2005; NICE, 2014 ) and the results of major pragmatic studies. Varying, and broad definitions of TRS and other issues in methodology mentioned earlier in this Letter may cause problems affecting the interpretation of studies. Indeed, metaanalyses of original studies with low quality methods lead to flawed conclusions. Future efforts must ideally focus on 1. well-characterized TRS samples (e.g. description of symptoms that predominate, onset of resistance, earlier used antipsychotics), 2. consensus definition of TRS to facilitate global interpretation and replication of results (e.g. WHO has produced with an expert panel consensus definition for severe asthma and this is something we need for TRS as well), 3. sample sizes even above 300 participants "to have power to clearly show a difference of 20% between groups for binary outcomes" (Sinclair and Adams, 2014) , and 4. studies without industry-sponsorship.
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